
    
      The purpose of this study is to determine whether or not intravenous immunoglobulin (lVlg),
      brand name Privigen, is effective in treating a disorder called HIV-associated myelopathy
      (HIVM). This drug is currently not approved by the Food and Drug Administration (FDA) for
      treating this disorder.

      HIVM is a spinal cord disease that occurs at any stage of HIV infection. It is not known what
      causes this condition, but symptoms can include weakness in the lower body and problems with
      frequent urination or problems with bowel function, trouble walking or performing sexually.
    
  